At the news
? NEUTRALIMPACT 5/10 8-K filed Feb 25, 2026 at 16:05 ET
Revolution Medicines reported its 2025 financial results, highlighting a $1.1 billion net loss on $987.3 million in R&D expenses as it advances a broad late-stage oncology pipeline. The company maintains a strong $2.0 billion cash position and provided 2026 operating expense guidance of $1.6-$1.7 billion, reflecting continued heavy investment in clinical development.
- Cash, cash equivalents and marketable securities were $2.0 billion as of December 31, 2025
- R&D expenses were $987.3 million for 2025, up from $595.2 million in 2024
- Net loss was $1.1 billion for 2025, compared to $600.1 million in 2024
- 2026 GAAP operating expenses are guided to be between $1.6 and $1.7 billion
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access